Glucocorticoids and... infections, doping, surgery, sexuality;Corticoïdes et... infections, dopage, chirurgie et sexualité

Revue de Medecine Interne

Volumn 34, Issue 5, 2013, Pages 269-278

  Grossi, O ^a   Genereau T ^b  

^a Service des Maladies Infectieuses   (France)

^b Service de Medecine Interne   (France)

Author keywords

Doping; Glucocorticoids; Infection; Sexuality; Surgery

Indexed keywords

GLUCOCORTICOID; LIVE VACCINE; ORAL CONTRACEPTIVE AGENT;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; CONSULTATION; CORTICOSTEROID THERAPY; DOPING; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG MEGADOSE; EMPORIATRICS; HERPES ZOSTER; HUMAN; IMMUNOSTIMULATION; INFECTION; INFECTION CONTROL; INFECTION RISK; INTRAUTERINE CONTRACEPTIVE DEVICE; LONG TERM CARE; MEASLES; PAIN; PHYSICIAN ATTITUDE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTOSIS; PRESCRIPTION; SEXUALITY; SHORT SURVEY; SURGERY; SURGICAL TECHNIQUE; URINARY TRACT INFECTION; VOMITING;

CONTRACEPTION; DOPING IN SPORTS; GLUCOCORTICOIDS; HUMANS; OPPORTUNISTIC INFECTIONS; PAIN, POSTOPERATIVE; PERFORMANCE-ENHANCING SUBSTANCES; POSTOPERATIVE NAUSEA AND VOMITING; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84876729283     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.12.008     Document Type: Short Survey

References (109)

1. Dussauze H., Bourgault I., Doleris L.M., Prinseau J., Baglin A., Hanslik T. Corticothérapie systémique et risque infectieux. Rev Med Interne 2007, 28:841-851.
2. Franklin J., Lunt M., Bunn D., Symmons D., Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007, 66:308-312.
3. Zandman-Goddard G., Shoenfeld Y. Infections and SLE. Autoimmunity 2005, 38:473-485.
4. Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11:229.
5. Chatam W. Glucocorticoid effect on the immune system. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
6. Klein N.C., Go C.H., Cunha B.A. Infections associated with steroid use. Infect Dis Clin North Am 2001, 15:423-432.
7. Saag K, Furst D. Major side effects of systemic glucocorticoids. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
8. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
9. Sowden E., Carmichael A.J. Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 2004, 4:42.
10. Gil H., Magy N., Mauny F., Dupond J.L. Valeur de l'éosinopénie dans le diagnostic des syndromes inflammatoires : un « vieux » marqueur revisité. Rev Med Interne 2003, 24:431-435.
11. Hajek V., Pasquet F., Karkowski L., Lachenal F., Gerôme P., Pavic M. Profil étiologique et pronostique des valeurs extrêmes (≥ 500 mg/L) de protéine C-réactive : étude rétrospective de 168 valeurs chez 113 patients. Rev Med Interne 2011, 32:663-668.
12. Buhaescu I., Yood R.A., Izzedine H. Serum procalcitonin in systemic autoimmune diseases-where are we now. Semin Arthritis Rheum 2010, 40:176-183.
13. Antona D., Delarocque-Astagneau E., Roudot-Thoraval F. épidémiologie de l'hépatite B. Hépatite B 2009, 77-89. EDK, Sèvre. J.M. Pawlotsky et, D. Dhumeaux (Eds.).
14. Lalazar G., Souhval D. Dépistage, prévention et traitement de la réactivation virale B en oncohématologie et chez les patients immunodéprimés. Hépatite B 2009, 443-457. EDK, Sèvre. J.M. Pawlotsky et, D. Dhumeaux (Eds.).
15. Terrier B., Pol S., Thibault V., Gottenberg J.E., Cacoub P. Prise en charge du risque de réactivation du virus de l'hépatite B chez les patients traités par immunosuppresseurs et immunomodulateurs en médecine interne : données de l'enquête REACTI-B et proposition d'un algorithme de prise en charge. Rev Med Interne 2012, 33:4-12.
16. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
17. Lok A.S.F., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
18. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
19. Le calendrier des vaccinations et les recommandations vaccinales 2012 selon l'avis du Haut Conseil de la Santé Publique. Institut de Veille Sanitaire. Bulletin épidémiologique Hebdomadaire no 14-15 du avril 2012.
20. Van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
21. Jick S.S., Lieberman E.S., Rahman M.U., Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.
22. Société de pneumologie de langue française Recommandations pour la prise en charge de la tuberculose en France. Rev Mal Respir 2004, 21:414-420.
23. Prévention et prise en charge de la tuberculose en France [Site Internet]. Conseil Supérieur d'Hygiène Publique de France 2003. Consultable sur : http://www.sante.gouv.fr/IMG/pdf/Synthese_et_recommandations_du_groupe_de_travail_sur_la_prevention_et_prise_en_charge_de_la_tuberculose_en_France_2002-2003_.pdf.
24. La tuberculose : dépistage et diagnostic précoce [Site Internet]. Institut National d'éducation et de Prévention pour la Santé. Consultable sur : http://www.inpes.sante.fr/CFESBases/catalogue/pdf/1183.pdf.
25. American Thoracic Society Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000, 49:1-51.
26. Horsburgh C.R., Rubin E.J. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011, 364:1441-1448.
27. Pai M, Menzies D. Diagnosis of latent tuberculosis infection in HIV-negative adults. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
28. Tuberculose et test de détection de l'interféron gamma [Site Internet]. Haut Conseil de la Santé Publique; 2011. Disponible sur : http://www.hcsp.fr/docspdf/avisrapports/hcspr20110701_interferongamma.pdf.
29. Mariette X., Baron G., Tubach F., Lioté F., Combe B., Miceli-Richard C., et al. Influence of replacing tuberculin skin test with ex vivo interferon - release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012, 71:1783-1790.
30. Mow W.S., Abreu-Martin M.T., Papadakis K.A., Pitchon H.E., Targan S.R., Vasiliauskas E.A. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004, 2:309-313.
31. Kunst H., Khan K.S. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010, 14:1374-1381.
32. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71:5-13.
33. Thomas C, Limper A. Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
34. Thomas C, Limper A. Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
35. Ward M.M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999, 42:780-789.
36. Vananuvat P., Suwannalai P., Sungkanuparph S., Limsuwan T., Ngamjanyaporn P., Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011, 41:497-502.
37. Ognibene F.P., Shelhamer J.H., Hoffman G.S., Kerr G.S., Reda D., Fauci A.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151:795-799.
38. Li J., Huang X.-M., Fang W.-G., Zeng X.-J. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol 2006, 12:114-117.
39. Thomas C.F., Limper A.H. Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
40. Meuli K., Chapman P., O'Donnell J., Frampton C., Stamp L. Audit of Pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Intern Med J 2007, 37:687-692.
41. White E.S., Lynch J.P. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006, 66:1209-1228.
42. Godeau B., Coutant-Perronne V., Le Thi Huong D., Guillevin L., Magadur G., De Bandt M., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994, 21:246-251.
43. Godeau B., Mainardi J.L., Roudot-Thoraval F., Hachulla E., Guillevin L., Huong Du L.T., et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995, 54:991-994.
44. Mansharamani N.G., Balachandran D., Vernovsky I., Garland R., Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000, 118:712-720.
45. Infections urinaires nosocomiales de l'adulte : conférence de consensus de la Société de pathologie infectieuse de langue française et de l'Association française d'urologie 2002. Texte court. Med Mal Infect 2003;23:375-80.
46. Nicolle L.E., Bradley S., Colgan R., Rice J.C., Schaeffer A., Hooton T.M. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005, 40:643-654.
47. Rakusa M., Murphy O., McIntyre L., Porter B., Panicker J., Fowler C., et al. Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis. Eur J Neurol 2012, 10.1111/j.1468-1331.2012.03806.x.
48. Saint S., Kaufman S.R., Rogers M.A.M., Baker P.D., Boyko E.J., Lipsky B.A. Risk factors for nosocomial urinary tract-related bacteremia: a case-control study. Am J Infect Control 2006, 34:401-407.
49. Fardet L., Généreau T., Cabane J., Kettaneh A. Severe strongyloidiasis in corticosteroid-treated patients. Clin Microbiol Infect 2006, 12:945-947.
50. Fardet L., Généreau T., Poirot J.L., Guidet B., Kettaneh A., Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 2007, 54:18-27.
51. Archibald L.K., Beeching N.J., Gill G.V., Bailey J.W., Bell D.R. Albendazole is effective treatment for chronic strongyloidiasis. Q J Med 1993, 86:191-195.
52. Bisoffi Z., Buonfrate D., Angheben A., Boscolo M., Anselmi M., Marocco S., et al. Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis. PLoS Negl Trop Dis 2011, 5:e1254.
53. Gann P.H., Neva F.A., Gam A.A. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994, 169:1076-1079.
54. Marti H., Haji H.J., Savioli L., Chwaya H.M., Mgeni A.F., Ameir J.S., et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996, 55:477-481.
55. Suputtamongkol Y., Kungpanichkul N., Silpasakorn S., Beeching N.J. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents 2008, 31:46-49.
56. Igual-Adell R., Oltra-Alcaraz C., Soler-Company E., Sánchez-Sánchez P., Matogo-Oyana J., Rodríguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004, 5:2615-2619.
57. Circulaire DGS/SD7A/SD5C/DHOS/E4 no 2002/243 du 22 avril 2002 relative à la prévention du risque lié aux légionelles dans les établissements de santé [Site Internet]. Disponible sur : http://www.sante.gouv.fr/fichiers/bo/2002/02-18/a0181819.htm.
58. Chidiac C., Che D., Pires-Cronenberger S., Jarraud S., Campèse C., Bissery A., et al. Factors associated with hospital mortality in community-acquired legionellosis in France. Eur Respir J 2012, 39:963-970.
59. Pedro-Botet M, Stout J, Yu V. Epidemiology and pathogenesis of Legionella infection. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
60. Albrecht M. Post-exposure prophylaxis against varicella-zoster virus infection UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
61. Albrecht M. Clinical features of varicella-zoster virus infection: chickenpox. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
62. Prise en charge des infections à VZV. Texte court de la 11e conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française. Presse Med 1998;27:1231-6.
63. Direction Générale de la Santé, Comité technique des vaccinations. Guide des vaccinations. édition 2012. Saint-Denis: Inpes, coll. Varia; 2012. 488 p.
64. Marin M., Güris D., Chaves S.S., Schmid S., Seward J.F. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1-40.
65. Barinaga J, Skolnik P. Prevention and treatment of measles. UpToDate 2012. (consulté le 21 oct 2012). http://www.uptodate.com/home.
66. Recommandations sanitaires pour les voyageurs. Comité des maladies liées aux voyages et des maladies d'importation, Haut Conseil de la Santé Publique. Institut de Veille Sanitaire. Bulletin épidémiologique Hebdomadaire no 20-21 du 29 mai 2012.
67. De Roux A., Marx A., Burkhardt O., Schweiger B., Borkowski A., Banzhoff A., et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2006, 24:1537-1542.
68. Lahood N., Emerson S.S., Kumar P., Sorensen R.U. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 1993, 70:289-294.
69. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362:812-822.
70. Rapport d'activité 2011 du Centre national de référence du pneumocoque [Site Internet]. Paris: Hopital européen Georges-Pompidou; 2011. http://www.invs.sante.fr/Espace-professionnels/Centres-nationaux-de-reference/Rapports-d-activites-et-liens.
71. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61:816-9.
72. Jong E, Freedman D. Immunocompromised travelers. Centers for Disease Control and Prevention. [Site Internet] CDC Health Information for International Travel 2012. (consulté le 21 oct 2012). http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers.htm.
73. Autorisation d'usage à des fins thérapeutiques (AUT) [Site Internet]. Agence française de lutte contre le dopage. (consulté le 30 novembre 2012). https://www.afld.fr/aut.
74. Orchard J.W. Why glucocorticoids should be removed from the World Antidoping Agency's list of banned products. Br J Sports Med 2008, 42:944-945.
75. Pluim B. A doping sinner is not always a cheat. Br J Sports Med 2008, 42:549-550.
76. Montalvan B., Duclos M. Why glucocorticoids ought to be kept on the World Antidoping Agency's list of banned products. Br J Sports Med 2008, 42:946-947.
77. Listes des fédérations sportives agréées [Internet]. Ministère des Sports, de la Jeunesse, de l'éducation populaire et de la Vie associative. (consulté le 30 novembre 2012). http://www.sports.gouv.fr/index/acteurs-du-sport/les-federations/liste-des-federations-sportives-2742.
78. Rapport d'activité 2011 [Site Internet]. Agence française de lutte contre le dopage. (consulté le 30 novembre 2012). https://www.afld.fr/documentation/recherche-de-documentation/rapport-relatif-7.
79. AFLD [Site Internet]. (consulté le 30 novembre 2012). https://www.afld.fr/.
80. Dvorak J., Feddermann N., Grimm K. Glucocorticosteroids in football: use and misuse. Br J Sports Med 2006, 40(Suppl. 1):i48-i54.
81. Duclos M. Glucocorticoids: a doping agent. Endocrinol Metab Clin North Am 2010, 39:107-126.
82. Tscholl P., Junge A., Dvorak J. The use of medication and nutritional supplements during FIFA World Cups 2002 and 2006. Br J Sports Med 2008, 42:725-730.
83. Henzi I., Walder B., Tramèr M.R. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000, 90:186-194.
84. Feo C.V., Sortini D., Ragazzi R., De Palma M., Liboni A. Randomized clinical trial of the effect of preoperative dexamethasone on nausea and vomiting after laparoscopic cholecystectomy. Br J Surg 2006, 93:295-299.
85. Romundstad L., Breivik H., Niemi G., Helle A., Stubhaug A. Methylprednisolone intravenously 1day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiol Scand 2004, 48:1223-1231.
86. Afman C.E., Welge J.A., Steward D.L. Steroids for post-tonsillectomy pain reduction: meta-analysis of randomized controlled trials. Otolaryngol Head Neck Surg 2006, 134:181-186.
87. Nagelschmidt M., Fu Z.X., Saad S., Dimmeler S., Neugebauer E. Preoperative high dose methylprednisolone improves patients outcome after abdominal surgery. Eur J Surg 1999, 165:971-978.
88. Laflin M.J. Interaction of pancuronium and corticosteroids. Anesthesiology 1977, 47:471-472.
89. Durmus M., Karaaslan E., Ozturk E., Gulec M., Iraz M., Edali N., et al. The effects of single-dose dexamethasone on wound healing in rats. Anesth Analg 2003, 97:1377-1380.
90. Baca B., Ozben V., Boler D.E., Onur E., Hamzaoglu I., Karahasanoglu T., et al. Effect of corticosteroid dose and duration of administration on colonic anastomosis. Inflamm Bowel Dis 2010, 16:2162-2167.
91. Aberra F.N., Lewis J.D., Hass D., Rombeau J.L., Osborne B., Lichtenstein G.R. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003, 125:320-327.
92. El-Hussuna A., Andersen J., Bisgaard T., Jess P., Henriksen M., Oehlenschlager J., et al. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. Scand J Gastroenterol 2012, 47:662-668.
93. Su F.W., Beckman D.B., Yarnold P.A., Grammer L.C. Low incidence of complications in asthmatic patients treated with preoperative corticosteroids. Allergy Asthma Proc 2004, 25:327-333.
94. Luca F, Taquet MC, Goichot B. Insuffisance surrénalienne cortico-induite. Rev Med Interne, doi:10.1016/j.revmed.2012.12.001.
95. Salem M., Tainsh R.E., Bromberg J., Loriaux D.L., Chernow B. Perioperative glucocorticoid coverage. A reassessment 42years after emergence of a problem. Ann Surg 1994, 219:416-425.
96. Marik P.E., Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg 2008, 143:1222-1226.
97. Jung C., Inder W.J. Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust 2008, 188:409-413.
98. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Généreau T., Tolédano C., et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007, 157:142-148.
99. Fardet L., Petersen I., Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012, 169:491-497.
100. Pfaus J.G. Pathways of sexual desire. J Sex Med 2009, 6:1506-1533.
101. Gesquiere L.R., Khan M., Shek L., Wango T.L., Wango E.O., Alberts S.C., et al. Coping with a challenging environment: effects of seasonal variability and reproductive status on glucocorticoid concentrations of female baboons (Papio cynocephalus). Horm Behav 2008, 54:410-416.
102. Harris B.N., Perea-Rodriguez J.P., Saltzman W. Acute effects of corticosterone injection on paternal behavior in California mouse (Peromyscus californicus) fathers. Horm Behav 2011, 60:666-675.
103. Lee E.E., Nieman L.K., Martinez P.E., Harsh V.L., Rubinow D.R., Schmidt P.J. ACTH and cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria during GnRH agonist-induced hypogonadism and ovarian steroid replacement. J Clin Endocrinol Metab 2012, 97:1887-1896.
104. Janssen N.M., Genta M.S. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000, 160:610-619.
105. Zerner J., Miller B.A., Festino M.J. Failure of an intrauterine device concurrent with administration of corticosteroids. Fertil Steril 1976, 27:1467-1468.
106. Inkeles D.M., Hansen R.I. Unexpected pregnancy in a woman using an intrauterine device and receiving steroid therapy. Ann Ophthalmol 1982, 14:975.
107. Thonneau P., Almont T., De La Rochebrochard E., Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006, 21:2612-2616.
108. Browne H., Manipalviratn S., Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol 2008, 112:667-669.
109. Yazdany J., Trupin L., Kaiser R., Schmajuk G., Gillis J.Z., Chakravarty E., et al. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality. Arthritis Care Res 2011, 63:358-365.